Evidence map›Paper›PMID 24903338›Full record

ArticleCarcinogenesis2014

SUMOylation of the ING1b tumor suppressor regulates gene transcription.

Shankha Satpathy, Claire Guérillon, Tae-Sun Kim, Nicolas Bigot, Satbir Thakur, Shirin Bonni, Karl Riabowol, Rémy Pedeux

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. MicroRNA Regulation of Oxidative Stress-Induced Cellular Senescence.Oxidative medicine and cellular longevity · 2017
    Review
  6. The interplay of post-translational modification and gene therapy.Drug design, development and therapy · 2016
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Shankha SatpathyDepartment of Biochemistry and Molecular Biology, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada, Present address: The Novo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.
Claire GuérillonINSERM U917, Microenvironnement et Cancer, 350043 Rennes, France, Université de Rennes 1, 350043 Rennes, France and.
Tae-Sun KimDepartment of Biochemistry and Molecular Biology, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Nicolas BigotINSERM U917, Microenvironnement et Cancer, 350043 Rennes, France, Université de Rennes 1, 350043 Rennes, France and.
Satbir ThakurINSERM U917, Microenvironnement et Cancer, 350043 Rennes, France.
Shirin BonniINSERM U917, Microenvironnement et Cancer, 350043 Rennes, France.
Karl RiabowolDepartment of Biochemistry and Molecular Biology, Southern Alberta Cancer Research Institute, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada, karl@ucalgary.ca.
Rémy PedeuxINSERM U917, Microenvironnement et Cancer, 350043 Rennes, France.
University of Calgary · CAFoie, Métabolisme, Cancer · FRInserm · FRUniversité de Rennes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The INhibitor of Growth (ING) proteins are encoded as multiple isoforms in five ING genes (ING1 -5) and act as type II tumor suppressors. They are growth inhibitory when overexpressed and are frequently mislocalized or downregulated in several forms of cancer. ING1 and ING2 are stoichiometric members of histone deacetylase complexes, whereas ING3-5 are stoichiometric components of different histone acetyltransferase complexes. The INGs target these complexes to histone marks, thus acting as epigenetic regulators. ING proteins affect angiogenesis, apoptosis, DNA repair, metastasis and senescence, but how the proteins themselves are regulated is not yet clear. Here, we find a small ubiquitin-like modification (SUMOylation) of the ING1b protein and identify lysine 193 (K193) as the preferred ING1b SUMO acceptor site. We also show that PIAS4 is the E3 SUMO ligase responsible for ING1b SUMOylation on K193. Sequence alignment reveals that the SUMO consensus site on ING1b contains a phosphorylation-dependent SUMOylation motif (PDSM) and our data indicate that the SUMOylation on K193 is enhanced by the S199D phosphomimic mutant. Using an ING1b protein mutated at the major SUMOylation site (ING1b E195A), we further demonstrate that ING1b SUMOylation regulates the binding of ING1b to the ISG15 and DGCR8 promoters, consequently regulating ISG15 and DGCR8 transcription. These results suggest a role for ING1b SUMOylation in the regulation of gene transcription.

Indexed as

SumoylationAmino Acid MotifsCytokinesGene Expression RegulationGenes, Tumor SuppressorHEK293 CellsHomeodomain ProteinsHumansLysinePoly-ADP-Ribose Binding ProteinsPromoter Regions, GeneticProtein Inhibitors of Activated STATReceptors, Cytoplasmic and NuclearRNA-Binding ProteinsTumor Suppressor ProteinsUbiquitin-Conjugating EnzymesCytokinesDGCR8 protein, humanHomeodomain ProteinsING2 protein, humanISG15 protein, humanLysinePIAS4 protein, humanPoly-ADP-Ribose Binding ProteinsProtein Inhibitors of Activated STATReceptors, Cytoplasmic and NuclearRNA-Binding ProteinsTumor Suppressor ProteinsUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9Ubiquitins

Identifiers

PMID24903338
PMCPMC4178466
OpenAlexW2141358350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.